On January 12, NP-G2-044 (Prilukae), a novel oral fascin inhibitor earned ODD for the treatment of pancreatic cancer. This designation covers the use of the agent as monotherapy and in combination ...

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...

Learn how radiopharmaceuticals are transforming cancer treatment and creating new opportunities for biotech and pharma ...

Infleqtion has been selected to advance to Phase 3 of the Q4Bio Challenge, a global program demonstrating quantum-enabled solutions for human health.

Tempus AI recently reported clinical validation results showing its Immune Profile Score (IPS) more accurately predicts outcomes for patients on immune checkpoint inhibitors than conventional ...

A paper published in Biology Methods and Protocols, indicates that a new computational method may help researchers identify ...

As integrative oncology gains attention, a protocol-driven model offers a clear message which is that metabolic and dietary therapies may enhance cancer care but only when anchored firmly to ...

BIRMINGHAM, Ala. (KFSN) -- According to the American Cancer Society, one in nine men will be diagnosed with prostate cancer at some point during his lifetime. The standard of care is usually surgery, ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...

Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here.

Cancer is no longer a rare disease. With rising life expectancy, changing lifestyles, pollution, and late detection, the cancer burden continues to gr.